Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy

Antiviral Research

Volumn 85, Issue 1, 2010, Pages 101-118

  McColl, Damian J ^a   Chen, Xiaowu ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Drug resistance; Elvitegravir (EVG); HIV 1; Integrase (IN); Integrase strand transfer inhibitor (INSTI); Raltegravir (RAL)

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; ASPARTIC ACID; DARUNAVIR; DOUBLE STRANDED DNA; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; GLUTAMIC ACID; GS 9350; GSK 1349572; INTEGRASE; INTEGRASE INHIBITOR; LAMIVUDINE; MARAVIROC; METAL ION; PENETRATION ENHANCING AGENT; PLACEBO; POL PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA;

ABNORMAL DREAMING; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CHELATION; CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIDE EFFECT; STRUCTURAL GENE; VIRUS GENE; VIRUS REPLICATION;

ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; PYRROLIDINONES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 73549123203     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.11.004     Document Type: Review

References (112)

1. Alian A., Griner S.L., Chiang V., Tsiang M., Jones G., Birkus G., Geleziunas R., Leavitt A.D., and Stroud R.M. Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proceedings of the National Academy of Sciences United States of America 106 (2009) 8192-8197
2. Arribas J.R., Pozniak A.L., Gallant J.E., Dejesus E., Gazzard B., Campo R.E., Chen S.S., McColl D., Holmes C.B., Enejosa J., Toole J.J., and Cheng A.K. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. Journal of Acquired Immune Deficiency Syndromes (JAIDS) 47 (2008) 74-78
3. Bartlett J.A., Chen S.S., and Quinn J.B. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clinical Trials 8 (2007) 221-226
4. Billich A. S-1360 Shionogi-GlaxoSmithKline. Current Opinion in Investigational Drugs 4 (2003) 206-209
5. Bouziane M., Cherny D.I., Mouscadet J.F., and Auclair C. Alternate strand DNA triple helix-mediated inhibition of HIV-1 U5 long terminal repeat integration in vitro. Journal of Biological Chemistry 271 (1996) 10359-10364
6. Bukrinsky M., Sharova N., and Stevenson M. Human immunodeficiency virus type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex. Journal of Virology 67 (1993) 6863-6865
7. Burke C.J., Sanyal G., Bruner M.W., Ryan J.A., LaFemina R.L., Robbins H.L., Zeft A.S., Middaugh C.R., and Cordingley M.G. Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase. Journal of Biological Chemistry 267 (1992) 9639-9644
8. Bushman F.D. Host proteins in retroviral cDNA integration. Advances in Virus Research 52 (1999) 301-317
9. Bushman F.D., Engelman A., Palmer I., Wingfield P., and Craigie R. Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proceedings of the National Academy of Sciences United States of America 90 (1993) 3428-3432
10. Bushman F.D., Fujiwara T., and Craigie R. Retroviral DNA integration directed by HIV integration protein in vitro (Abstract). Science 249 (1990) 1555-1558
11. Cai, M., Zheng, R., Cafferey, M., Craigie, R., Clore, G.M., A.M., G., 1997. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase (Abstract). Nature Structural Biology 4, 567-577.
12. Ceccherini-Silberstein F., Armenia D., D'Arrigo R., Micheli V., Fabeni L., Meraviglia P., Capetti A., Zaccarelli M., Trotta M.P., Narciso P., Antinori A., and Perno C.F. Virological response and resistance in multi-experienced patients treated with raltegravir (poster 18). XVII International HIV Drug Resistance Workshop. Sitges, Spain (2008)
13. Cihlar T., and Ray A. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 year after zidovudine. Antiviral Research 85 (2010)
14. Colicelli J., and Goff S.P. Sequence and spacing requirements of a retrovirus integration site (Abstract). Journal of Molecular Biology 199 (1988) 47-59
15. Cooper D.A., Steigbigel R.T., Gatell J., Rockstroh J., Katlama C., Yeni P., Lazzarin A., Clotet B., Kumar P., Eron J.E., Schechter M., Markowitz M., Loutfy M.R., Lennox J.L., Zhao J., Chen J., Ryan D.M., Rhodes R.R., Killar J.A., Gilde L.R., Strohmaier K.M., Meibohm A.R., Miller M.D., Hazuda D.J., Nessly M.L., DiNubile M.J., Isaacs R.D., Teppler H., and Nguyen B. Subgroup and resistance analyses of raltegravir for resistance HIV-1 infection. New England Journal of Medicine 359 (2008) 355-365
16. Chen I.J., Neamati N., Nicklaus M.C., Orr A., Anderson L., Barchi Jr. J.J., Kelley J.A., Pommier Y., and MacKerell Jr. A.D. Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets. Bioorganic and Medicinal Chemistry 8 (2000) 2385-2398
17. Chen X., Tsiang M., Yu F., Hung M., Jones G.S., Zeynalzadegan A., Qi X., Jin H., Kim C.U., Swaminathan S., and Chen J.M. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. Journal of Molecular Biology 380 (2008) 504-519
18. Da Silva D., Pellegrin I., Anies G., Breilh D., Wittkop L., Morlat P., Dupon M., Neau D., Pellegrin J.L., Fleury H., and Masquelier B. Mutational patterns in the HIV-1 integrase related to virological failures on raltegravir-containing regimens (poster 12). XVII International HIV Drug Resistance Workshop. Sitges, Spain (2008)
19. Davies D.R., Goryshin I.Y., Reznikoff W.S., and Rayment I. Three-dimensional structure of the Tn5 synaptic complex transposition intermediate. Science 289 (2000) 77-85
20. de Bethune M.P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Research 85 (2010) XX-XX
21. DeJesus E., Berger D., Markowitz M., Cohen C., Hawkins T., Ruane P., Elion R., Farthing C., Cheng A., and Kearney B. The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naïve and experienced patients (oral number 36). Journal of Acquired Immune Deficiency Syndromes 43 (2006) 1-5
22. DeJesus E., Berger D., Markowitz M., Cohen C., Hawkins T., Ruane P., Elion R., Farthing C., Zhong L., Cheng A.K., McColl D., and Kearney B.P. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. Journal of Acquired Immune Deficiency Syndromes (JAIDS) 43 (2006) 1-5
23. Drelich M., Wilhelm R., and Mous J. Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in Vitro (Abstract). Virology 188 (1992) 459-468
24. Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R., and Davies D.R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases (Abstract). Science 266 (1994) 1981-1986
25. Ellison V., Gerton J., Vincent K.A., and Brown P.O. An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer. Journal of Biological Chemistry 270 (1995) 3320-3326
26. Engelman A., Bushman F.D., and Craigie R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO Journal 12 (1993) 3269-3275
27. Engelman A., and Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. Journal of Virology 66 (1992) 6361-6369
28. Eron J., Andrade J., Zajdenverg R., Workman C., Cooper D., Young B., Xu X., Nguyen B.Y., Leavitt R., and Sklar P. Switching from stable lopinavir/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24 (abstract 70aLB). 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montréal, Canada (2009)
29. Espeseth A.S., Felock P., Wolfe A., Witmer M., Grobler J., Anthony N., Egbertson M., Melamed J.Y., Young S., Hamill T., Cole J.L., and Hazuda D.J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proceeding of the National Academy of Sciences United States of America 97 (2000) 11244-11249
30. Farnet C.M., and Bushman F.D. HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 88 (1997) 483-492
31. Fesen M.R., Kohn K.W., Leteurtre F., and Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proceedings of the National Academy Sciences United States of America 90 (1993) 2399-2403
32. Fikkert V., Hombrouck A., Van Remoortel B., De Maeyer M., Pannecouque C., De Clercq E., Debyser Z., and Witvrouw M. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 18 (2004) 2019-2028
33. Fikkert V., Van Maele B., Vercammen J., Hantson A., Van Remoortel B., Michiels M., Gurnari C., Pannecouque C., De Maeyer M., Engelborghs Y., De Clercq E., Debyser Z., and Witvrouw M. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. Journal of Virology 77 (2003) 11459-11470
34. Fransen S., Gupta S., Danovich R., Hazuda D., Miller M., Witmer M., Petropoulos C.J., Parkin N.T., and Huang W. Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways (poster 7). XVII International HIV Drug Resistance Workshop. Sitges, Spain (2008)
35. Gao K., Gorelick R.J., Johnson D.G., and Bushman F. Cofactors for human immunodeficiency virus type 1 cDNA integration in vitro. Journal of Virology 77 (2003) 1598-1603
36. Garvey E.P., Johns B.A., Gartland M.J., Foster S.A., Miller W.H., Ferris R.G., Hazen R.J., Underwood M.R., Boros E.E., Thompson J.B., Weatherhead J.G., Koble C.S., Allen S.H., Schaller L.T., Sherrill R.G., Yoshinaga T., Kobayashi M., Wakasa-Morimoto C., Miki S., Nakahara K., Noshi T., Sato A., and Fujiwara T. The naphthyridinone GSK-364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrobial Agents and Chemotherapy 52 (2008) 901-908
37. Goethals O., Clayton R., Wagemans E., Van Ginderen M., Cummings M., Geluykens P., Dockx K., Smits V., Meersseman G., Jochmans D., Hallenberger S., and Hertogs K. Resistance mutations in HIV-1 integrase selected with raltegravir or elvitegravir confer reduced susceptibility to a diverse panel of integrase inhibitors (poster 9). XVII International HIV Drug Resistance Workshop (IHDRW). Sitges, Spain (2008)
38. Goff S.P. Genetics of retroviral integration (Abstract). Annual Review of Genetics 26 (1992) 527-544
39. Goldgur Y., Craigie R., Cohen G.H., Fujiwara T., Yoshinaga T., Fujishita T., Sugimoto H., Endo T., Murai H., and Davies D.R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proceedings of National Academy of Sciences United States of America 96 (1999) 13040-13043
40. Goodman D.D., Hluhanich R., Waters J.M., Margot N.A., Fransen S., Gupta S., Huang W., Parkin N., Borroto-Esoda K., Svarovskaia E.S., Miller M.D., and McColl D.J. Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: a novel mutation L68V/I associates with E92Q and increases resistance (poster 13). XVII International HIV Drug Resistance Workshop. Stiges, Spain (2008)
41. Grinsztejn B., Nguyen B., Katlama C., Gatell J., Lazzarain A., Vittecoq D., Gonzalex C., Chen J., and Isaacs R. 48 week efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus (abstract H-173). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA (2007)
42. Grobler J.A., Stillmock K., Hu B., Witmer M., Felock P., Espeseth A.S., Wolfe A., Egbertson M., Bourgeois M., Melamed J., Wai J.S., Young S., Vacca J., and Hazuda D.J. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proceedings of the National Academy of Sciences United States of America 99 (2002) 6661-6666
43. Hatano H., Lampiris H., Huang W., Hoh R., Gupta S., Fransen S., Martin J.N., Petropoulous C., and Deeks S.G. Virologic and immunologic outcomes in a cohort of subjects failing integrase inhibitors (poster 2725). XVII International HIV Drug Resistance Workshop. Sitges, Spain (2008)
44. Hazuda D., Blau C.U., Felock P., Hastings J., Pramanik B., Wolfe A., Bushman F., Famet C., Goetz M., Williams M., Silverman K., Lingham R., and Singh S. Isolation and characterization of novel human immunodeficiency virus integrase inhibitors from fungal metabolites (Abstract). Antiviral Chemistry and Chemotherapy 10 (1999) 63-70
45. Hazuda D.J., Anthony N.J., Gomez R.P., Jolly S.M., Wai J.S., Zhuang L., Fisher T.E., Embrey M., Guare Jr. J.P., Egbertson M.S., Vacca J.P., Huff J.R., Felock P.J., Witmer M.V., Stillmock K.A., Danovich R., Grobler J., Miller M.D., Espeseth A.S., Jin L., Chen I.W., Lin J.H., Kassahun K., Ellis J.D., Wong B.K., Xu W., Pearson P.G., Schleif W.A., Cortese R., Emini E., Summa V., Holloway M.K., and Young S.D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proceedings of the National Academy of Sciences United States of America 101 (2004) 11233-11238
46. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., and Miller M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287 (2000) 646-650
47. Hazuda D.J., Hastings J.C., Wolfe A.L., and Emini E.A. A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Research 22 (1994) 1121-1122
48. Hazuda D.J., Miller M.D., Nguyen B.Y., and Zhao J. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase 2 study in patients with triple-class resistant HIV-1 infection (poster #8). 16th International HIV Drug Resistance Workshop. Bridgetown, Barbados (2007)
49. Hombrouck A., Voet A., Van Remoortel B., Desadeleer C., De Maeyer M., Debyser Z., and Witvrouw M. Mutations in HIV-1 integrase confer resistance to the naphthyridine L-870,810 and cross resistance to the clinical trial drug GS-9137. Antimicrobial Agents and Chemotherapy (2008)
50. Johnson A.A., Santos W., Pais G.C., Marchand C., Amin R., Burke Jr. T.R., Verdine G., and Pommier Y. Integration requires a specific interaction of the donor DNA terminal 5′-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. Journal of Biological Chemistry 281 (2006) 461-467
51. Jones G., Ledford R.M., Yu F., Chen X., Miller M.D., Tsiang M., and McColl D.J. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor GS-9137 (JTK-303) (slides-poster #627). 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA (2007)
52. Jones G.S., Yu F., Zeynalzadegan A., Hesselgesser J., Chen X., Chen J., Jin H., Kim C.U., Wright M., Geleziunas R., and Tsiang M. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrobial Agents and Chemotherapy 53 (2009) 1194-1203
53. Kalpana G.V., Marmon S., Wang W., Crabtree G.R., and Goff S.P. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5 (Abstract). Science 266 (1994) 2002-2006
54. Katayanagi K., Okumara M., and Morikawa K. Crystal structure of Esherichia coli RNase HI in complex with Mg2+ at 2.8 A resolution: proof for a single Mg(2+)-binding site (Abstract). Proteins 17 (1993) 337-346
55. Katlama C., Caby F., Schneider L., Andrade R.M., Tubiana A., Valantin M.A., Ktorza N., Malet I., Peytavin G., Canestri A., and Calvez V. Virological evolution in HIV treatment-experienced patients with raltegravir-based salvage regimens (poster 11). XVII International HIV Drug Resistance Workshop. Sitges, Spain (2008)
56. Kawaguchi I., Ishikawa T., Ishibashi M., Irie S., and Kakee A. Safety and pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers (poster number 580). 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (2006)
57. Kearney B.P., Mathias A., Zhong L., DeJesus E., Markowitz M., Hawkins T., and Cheng A. Pharmacokinetics/pharmacodynamics of GS-9137 an HIV integrase inhibitor in treatment-naïve and experienced patients (abstract 73). 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal (2006)
58. King P.J., Lee D.J., Reinke R.A., Victoria J.G., Beale K., and Robinson Jr. W.E. Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology 306 (2003) 147-161
59. King P.J., and Robinson Jr. W.E. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. Journal of Virology 72 (1998) 8420-8424
60. Kobayashi M., Nakahara K., Seki T., Miki S., Kawauchi S., Suyama A., Wakasa-Morimoto C., Kodama M., Endoh T., Oosugi E., Matsushita Y., Murai H., Fujishita T., Yoshinaga T., Garvey E., Foster S., Underwood M., Johns B., Sato A., and Fujiwara T. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Research (2008) doi: 10.1016/j.antiviral.2008.06012
61. Kulkosky J., Jones K.S., Katz R.A., Mack J.P., and Skalka A.M. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Molecular and Cellular Biology 12 (1992) 2331-2338
62. LaFemina R.L., Callahan P.L., and Cordingley M.G. Substrate specificity of recombinant human immunodeficiency virus integrase protein. Journal of Virology 65 (1991) 5624-5630
63. Lalezari J., Sloan L., DeJesus E., Hawkins T., McCurdy L., Song I., Borland J., Stroder R., Chen S., Lou Y., Underwood M., Fujiwara T., Piscitelli S., and Min S. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-Naïve HIV-1-infected patients: ING111521 Protocol (Abstract TUAB105). IAS 2009-5th Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa (2009)
64. Lazzarin A., Campbell T., Clotet B., Johnson M., Katlama C., Moll A., Towner W., Trottier B., Peeters M., Vingerhoets J., de Smedt G., Baeten B., Beets G., Sinha R., and Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370 (2007) 39-48
65. Leavitt A.D., Rose R.B., and Varmus H.E. Both substrate and target oligonucleotide sequences affect in vitro integration mediated by human immunodeficiency virus type 1 integrase protein produced in Saccharomyces cerevisiae. Journal of Virology 66 (1992) 2359-2368
66. Lennox J., DeJesus E., Lazzarin A., Berger D., Pollard R., Madruga J., Zhao J., Gilbert C., Rodgers A., Teppler H., Nguyen B.Y., Leavitt R., and Sklar P. Raltegravir demonstrates durable efficacy through 96 weeks: results from STARTMRK, a phase III study of raltegravir-based vs. efavirenz-based therapy in treatment-naïve HIV+ patients (Poster H924b). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA (2009)
67. Lennox J.L., DeJesus E., Lazzarin A., Pollard R.B., Madruga J.V., Berger D.S., Zhao J., Xu X., Williams-Diaz A., Rodgers A.J., Barnard R.J., Miller M.D., DiNubile M.J., Nguyen B.Y., Leavitt R., and Sklar P. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374 (2009) 796-806
68. Li L., Yoder K., Hansen M.S., Olvera J., Miller M.D., and Bushman F.D. Retroviral cDNA integration: stimulation by HMG I family proteins. Journal of Virology 74 (2000) 10965-10974
69. Lin C.W., and Engelman A. The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes. Journal of Virology 77 (2003) 5030-5036
70. Little S., Drusano G., Schooley R., Haas D., Kumar P., Hammer S., McMahon D., Squires K., Asfour R., Richman D., Chen J., Saah A., Leavitt R., Hazuda D., Nguyen B.Y., and Protocol 004 Study Team. Antiretroviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1 infected patients (abstract 161). 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005)
71. Lubkowski J., Yang F., Alexandratos J., Wlodawer A., Zhao H., Burke Jr. T.R., Neamati N., Pommier Y., Merkel G., and Skalka A.M. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proceedings of the National Academy of Sciences United States of America 95 (1998) 4831-4836
72. Madruga J.V., Cahn P., Grinsztejn B., Haubrich R., Lalezari J., Mills A., Pialoux G., Wilkin T., Peeters M., Vingerhoets J., de Smedt G., Leopold L., Trefiglio R., and Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370 (2007) 29-38
73. Maertens G., Cherepanov P., Pluymers W., Busschots K., De Clercq E., Debyser Z., and Engelborghs Y. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. Journal of Biological Chemistry 278 (2003) 33528-33539
74. Marchand, C., Johnson, A.A., Karki, R.G., Pais, G.C., Zhang, X., Cowansage, K., Patel, T.A., Nicklaus, M.C., Burke, T.R., Pommier, Y., 2003. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S) 64, 600-609.
75. Marchand C., Zhang X., Pais G.C., Cowansage K., Neamati N., Burke Jr. T.R., and Pommier Y. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. Journal of Biological Chemistry 277 (2002) 12596-12603
76. Markowitz M., Morales-Ramirez J.O., Nguyen B.Y., Kovacs C.M., Steigbigel R.T., Cooper D.A., Liporace R., Schwartz R., Isaacs R., Gilde L.R., Wenning L., Zhao J., and Teppler H. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes (JAIDS) 43 (2006) 509-515
77. Markowitz M., Nguyen B.Y., Gotuzzo E., Mendo F., Ratanasuwan W., Kovacs C., Prada G., Morales-Ramirez J.O., Crumpacker C.S., Isaacs R.D., Gilde L.R., Wan H., Miller M.D., Wenning L.A., and Teppler H. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. Journal of Acquired Immune Deficiency Syndromes (JAIDS) 46 (2007) 125-133
78. McColl D.J., Fransen S., Gupta S., Parkin N., Margot N., Ledford R., Chen J., Chuck S., Cheng A.K., and Miller M.D. Resistance and cross-resistance to first generation integrase inhibitors: Insights from a phase 2 study of Elvitegravir (GS-9137) (abstract number 9). 16th International HIV Drug Resistance Workshop. Bridgetown, Barbados (2007)
79. Mekouar K., Mouscadet J.F., Desmaele D., Subra F., Leh H., Savoure D., Auclair C., and d'Angelo J. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. Journal of Medicinal Chemistry 41 (1998) 2846-2857
80. Miller M.D., Danovich R.M., Ke Y., Witmer M., Zhao J., Harvey C., Nguyen B.-Y., and Hazuda D. Longitudinal analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from P005, a phase 2 study in treatment experienced patients (poster). XVII International HIV Drug Resistance Workshop. Sitges, Spain (2008)
81. Miller M.D., Farnet C.M., and Bushman F.D. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. Journal of Virology 71 (1997) 5382-5390
82. Neamati N., Hong H., Owen J.M., Sunder S., Winslow H.E., Christensen J.L., Zhao H., Burke Jr. T.R., Milne G.W., and Pommier Y. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. Journal of Medicinal Chemistry 41 (1998) 3202-3209
83. Nicklaus M.C., Neamati N., Hong H., Mazumder A., Sunder S., Chen J., Milne G.W., and Pommier Y. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. Journal of Medicinal Chemistry 40 (1997) 920-929
84. Pommier Y., Johnson A.A., and Marchand C. Integrase inhibitors to treat HIV/AIDS. Nature Reviews Drug Discovery 4 (2005) 236-248
85. Raillard S.A., and Joyce G.F. Targeting sites within HIV-1 cDNA with a DNA-cleaving ribozyme. Biochemistry 35 (1996) 11693-11701
86. Rice P., Craigie R., and Davies D.R. Retroviral integrases and their cousins. Current Opinion in Structural Biology 6 (1996) 76-83
87. Rice P., and Mizuuchi K. Structure of the bacteriophage Mu transposase core: a common structural motif for DNA transposition and retroviral integration. Cell 82 (1995) 209-220
88. Robinson Jr. W.E., Cordeiro M., Abdel-Malek S., Jia Q., Chow S.A., Reinecke M.G., and Mitchell W.M. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Molecular Pharmacology 50 (1996) 846-855
89. Sato M., Motomura T., Aramaki H., Matsuda T., Yamashita M., Ito Y., Kawakami H., Matsuzaki Y., Watanabe W., Yamataka K., Ikeda S., Kodama E., Matsuoka M., and Shinkai H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. Journal of Medicinal Chemistry 49 (2006) 1506-1508
90. Schooley R.T., Ruane P., Myers R.A., Beall G., Lampiris H., Berger D., Chen S.-S., Miller M.D., Isaacson E., and Cheng A.K. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16 (2002) 1257-1263
91. Sherman P.A., and Fyfe J.A. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proceedings of the National Academy of Sciences United States of America 87 (1990) 5119-5123
92. Shimura K., Kodama E., Sakagami Y., Matsuzaki Y., Watanabe W., Yamataka K., Watanabe Y., Ohata Y., Doi S., Sato M., Kano M., Ikeda S., and Matsuoka M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). Journal of Virology 82 (2008) 764-774
93. Singh S.B., Zink D.L., Bills G.F., Teran A., Silverman K.C., Lingham R.B., Felock P., and Hazuda D.J. Four novel bis-(naphtho-gamma-pyrones) isolated from Fusarium species as inhibitors of HIV-1 integrase. Bioorganic & Medicinal Chemistry Letters 13 (2003) 713-717
94. Sioud M., and Drlica K. Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme. Proceedings of the National Academy of Sciences United States of America 88 (1991) 7303-7307
95. Steigbigel R.T., Cooper D.A., Eron J.E., Gatell J.M., Kumar P.N., Rockstroh J.K., Wan H., Sklar P., Teppler H., and Nguyen B.Y. 96-Week results from BENCHMRK 1&2, phase III studies of raltegravir (RAL) in patients (pts) failing antiretroviral therapy (ART) with triple-class resistant HIV (Poster 571b). 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montréal, Canada (2009)
96. Steigbigel R.T., Cooper D.A., Kumar P.N., Eron J.E., Schechter M., Markowitz M., Loutfy M.R., Lennox J.L., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., Lazzarin A., Clotet B., Zhao J., Chen J., Ryan D.M., Rhodes R.R., Killar J.A., Gilde L.R., Strohmaier K.M., Neibohm A.R., Miller M.D., Hazuda D.J., Nessly M.L., DiNubile M.J., Isaacs R.D., Nguyen B.Y., and Teppler H. Raltegravir with optimized background therapy for resistant HIV-1 infection. New England Journal of Medicine 359 (2008) 339-353
97. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., Hazuda D.J., Jones P., Kinzel O., Laufer R., Monteagudo E., Muraglia E., Nizi E., Orvieto F., Pace P., Pescatore G., Scarpelli R., Stillmock K., Witmer M.V., and Rowley M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. Journal of Medicinal Chemistry 51 (2008) 5843-5855
98. Tilton J.C., and Doms R.W. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Research 85 (2010)
99. Underwood M., Johns B., Sato A., Fujiwara T., and Spreen W. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy (Poster WEPEA098). IAS 2009-5th Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa (2009)
100. Vacca J., Wai J., Fisher T., Embrey M., Hazuda D., Miller M., Felock P., Witmer M., Gabryelski L., and Lyle T. Discovery of MK-2048-subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors (Abstract). 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention incorporating the 19th ASHM Conference. Sydney, Australia (2007)
101. van Gent D.C., Oude Groeneger A.A., and Plasterk R.H. Identification of amino acids in HIV-2 integrase involved in site-specific hydrolysis and alcoholysis of viral DNA termini. Nucleic Acids Research 21 (1993) 3373-3377
102. Vink C., and Plasterek R.H. The human immunodeficiency virus integrase protein (Abstract). Trends Genetics 9 (1993) 443-448
103. Wai J., Fisher T., Embrey M., Egbertson M., Vacca J., Hazuda D., Miller M., Witmer M., Gabryelski L., and Lyle T. Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: structural diversity and resistance profiles (Abstract 87). 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA (2007)
104. Waters J.M., Margot N., Hluhanich R., Svarovskaia J., Harris J., Borroto-Esoda K., Miller M.D., and McColl D.J. Evolution of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns (Poster P116). XVIII International HIV Drug Resistance Workshop. Fort Myers, Florida (2009)
105. Wensing, A.M.J., van Maarseveen, N.M., Nijhuys, M., 2010. HIV protease inhibitors. Antiviral Research 85.
106. Witmer M., Danovich R., Ke Y., Day A., Gabryelski L., Ecto L., Lu M., Lai M.-T., McKenna P., DiStefano D., Miller M., and Hazuda D. In vitro resistance selection studies using raltegravir: a novel inhibitor of HIV-1 integrase (abstract #17). 8th Annual Symposium on Antiviral Drug Resistance. Richmond, VA, USA (2007)
107. Yoder K.E., and Bushman F.D. Repair of gaps in retroviral DNA integration intermediates. Journal of Virology 74 (2000) 11191-11200
108. Zheng R., Jenkins T.M., and Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proceedings of the National Academy of Sciences United States of America 93 (1996) 13659-13664
109. Zhuang L., Wai J.S., Embrey M.W., Fisher T.E., Egbertson M.S., Payne L.S., Guare Jr. J.P., Vacca J.P., Hazuda D.J., Felock P.J., Wolfe A.L., Stillmock K.A., Witmer M.V., Moyer G., Schleif W.A., Gabryelski L.J., Leonard Y.M., Lynch Jr. J.J., Michelson S.R., and Young S.D. Design and synthesis of 8-hydroxy-(1,6)naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. Journal of Medicinal Chemistry 46 (2003) 453-456
110. Zolopa A.R., Lampiris H., Blick G., Walworth C., Zhong L., Chuck S.L., Enejosa J., Kearney B.P., and Cheng A.K. The HIV integrase inhibitor elvitegravir (EVG/r) has potent and durable antiretroviral activity in treatment-experienced patients with active optimized background therapy (OBT) (Oral Presentation). 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL (2007)
111. Zolopa, A.R., Mullen, M., Berger, D., Ruane, P., Hawkins, T., Zhong, L., Chuck, S.L., Enejosa, J., Kearney, B.P., K, C.A., 2007b. The HIV integrase inhibitor GS-9137 has potent antiretroviral activity in treatment-experienced patients (oral presentation 143LB). In: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA.
112. Zouhiri F., Mouscadet J.F., Mekouar K., Desmaele D., Savoure D., Leh H., Subra F., Le Bret M., Auclair C., and d'Angelo J. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. Journal of Medicinal Chemistry 43 (2000) 1533-1540